All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 1800+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Business Development

Servier in-licenses Black Diamond Therapeutics' BDTX-4933 (targeting RAS/RAF mutations) for $70M upfront with $710M in milestones
Small molecule, cancer, solid tumor - Read more

Pfizer completes sale of its 7.3% stake in consumer health company Haleon for £2.5B
Consumer health - Read more

PRESENTED BY DRUGBANK
The Next Evolution in Drug Discovery Intelligence is here - don’t get left behind.

Too often in drug discovery, researchers are stuck grappling with fragmented data sources, manual workflows, and missed opportunities.

That’s what this next evolution of DrugBank aims to solve:

We’ve consolidates fragmented drug intelligence into an intuitive AI-powered platform designed for biotech professionals to uncover insights, streamline decision-making, and accelerate drug discovery.

Be among the first to access the Future of Drug Discovery. Request Early Access Now.

⬇️ More Good News ⬇️

THE GOOD
Clinical Trials

Immunovant and Roivant's batoclimab (targeting FcRn) delivers significant symptom reduction in Ph3 trial in generalized myasthenia gravis
Monoclonal antibody, myasthenia gravis - Read more [Paywall]

REGENXBIO's gene therapy RGX-202 shows promising microdystrophin expression and safety profile in Ph1/2 trial for Duchenne muscular dystrophy
Gene therapy, Duchenne muscular dystrophy (DMD) - Read more

Novartis's intrathecal Zolgensma (targeting SMN1 gene) showed improvement in spinal muscular atrophy in older patients in Ph3 trial
Gene therapy, spinal muscular atrophy (SMA), drug delivery - Read more

Innovent and HUTCHMED's Ph2/3 trial of sintilimab (targeting PD-1) and fruquintinib (targeting VEGF) combo met progression-free survival endpoint for advanced renal cell carcinoma
Monoclonal antibody, small molecule, renal cell carcinoma, cancer, combo therapy - Read more

THE GOOD
Fundraises

Ampersand Biosciences $65M Series B, developing “smart medicines” for immuno-inflammation and immuno-oncology therapies
Inflammatory disease, cancer, undisclosed modality - Read more

Nemysis Limited lands investment from Avia Pharma, funding oral iron supplement IHAT and gluten-destroying therapy development
Supplement, enzyme - Read more

Proscia $50M funding, developing AI software to accelerate digital pathology for precision medicine
AI, pathology, precision medicine - Read more

Genenta Science $21.9M financing, advancing Temferon therapy for metastatic Renal Cell Cancer
Cell therapy, hematopoietic stem cell, renal cell carcinoma - Read more

THE GOOD
Investments

Federal government invests $49.9M in STEMCELL Technologies for vaccine production expansion, creating 460 jobs
Biomanufacturing, new facility - Read more

THE GOOD
Marketing

Aadi Bioscience rebrands as Whitehawk Therapeutics following pivot to preclinical ADC development; changes ticker to "WHWK."
Rebrand, antibody-drug conjugate (ADC) - Read more

THE GOOD
Mergers & Acquisition

Advanced Instruments acquires Nova Biomedical, creating a $621M global life science tools platform under Nova's name
Equipment/Instrumentation - Read more

THE GOOD
Partnerships

Roche, Oxford BioTherapeutics up to $1B partnership to develop antibody-based cancer therapies using OGAP-Verify platform
Antibody-drug conjugate (ADC), cancer, drug discovery - Read more

Primo, ABX strategic partnership to introduce PB01 prostate cancer radiotracer to Taiwan market
CT imaging, PET Scan, prostate cancer, imaging tracer, cancer imaging - Read more

Xcell Biosciences, Royal Perth Hospital collaborating to develop automated TIL therapy manufacturing workflow using AVATAR Foundry system
Automated manufacturing, cell therapy, tumor-infiltrating lymphocyte (TIL), cancer - Read more

CERo Therapeutics, University of California Davis partnership for manufacturing CER-1236 therapy for AML clinical trials
Cell therapy, myeloid leukemia, cancer, manufacturing partnership, T cell therapy - Read more

Synchron partners with NVIDIA to develop AI model trained on brain activity, aiming to improve BCI technology
Brain-computer interface, AI - Read more

THE GOOD
Patient Access

OptumRx eliminating prior authorization for 80 drugs starting May 1, cutting 25% of reauthorizations for various chronic conditions
Health insurance, prior authorization (health insurance) - Read more

THE GOOD
Research

Study shows dendritic cell vaccine combined with chemotherapy may improve outcomes for HER2-positive, ER-negative breast cancer patients
Dendritic cell vaccine, breast cancer - Read more

Lexaria Bioscience's oral DehydraTECH-tirzepatide capsules achieve similar bloodstream levels as injectable Zepbound, potentially offering alternative to weekly injections
GLP-1, obesity, drug delivery, oral formulation - Read more

Hoth Therapeutics' HT-KIT therapy shows promising preclinical results against gastrointestinal stromal tumors by targeting KIT mutations
Antisense oligonucleotide, cancer - Read more

AI neural network NicheCompass analyzes cell communication, predicting cancer progression to guide personalized treatments within one hour.
AI, spatial analysis, spatial biology, cell signaling - Read more

PRESENTED BY TLDR BIOTECH
What would you do with 6.5k+ meticulously tagged biotech & pharma data points?
*New* Sample Data Available - See below!

Over the past year, TLDR Biotech has been collecting and categorizing industry news across approvals, clinical trials, fundraises, partnerships, M&A, politics & policy, and much much more.

Each data point is tagged by drug modality, disease indication, tech area, and even more specific categories. For example:

🔍 Need to track all small molecule fundraises across oncology?

📈 Want a curated list of recent cell therapy clinical trials updates (both the successes and failures)?

💡 Looking for trends in Alzheimer's and Parkinson's disease partnerships?

Here’s a sample set of data - lung cancer stories over the last 3 months.

If you’re interested, send us an email [email protected] with the subject line “6K BIOTECH DATA” and we’ll chat further.*

*If you’ve received this newsletter as an email, just hit reply!

THE BAD
Earnings & Finances

Gilead stock drops as HHS considers cutting HIV prevention funding, threatening company's revenue
Federal funding, human immunodeficiency virus (HIV) - Read more

THE BAD
Lawsuits

Trump administration defends Biden-era abortion pill restrictions against lawsuit that claims FDA requirements are unnecessarily burdensome
Abortion, abortion access - Read more [Paywall]

THE BAD
Strategic Plans

Purdue Pharma proposes $7.4 billion bankruptcy reorganization plan to settle opioid claims after Supreme Court rejected previous settlement
Opioid epidemic, bankruptcy - Read more

THE UGLY
Layoffs

CARGO Therapeutics shuts down all R&D and lays off 90% of staff after CAR-T therapy failure due to safety concerns.
Cell therapy, CAR-T, B cell lymphoma - Read more

THE UGLY
Politics & Policy

Trump administration considering major cuts to CDC's HIV prevention division, potentially slashing $1.3 billion from the program
Centers for Disease Control and Prevention (CDC), human immunodeficiency virus (HIV), federal funding - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here